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The trend toward personalized management of diabetes has focused attention on
the differences among available pharmacological agents in terms of mechanisms
of action, efficacy, and, most important, safety. Clinicians must select from these
features to develop individualized therapy regimens. In June 2013, a nine-member
Diabetes Care Editors’ Expert Forum convened to review safety evidence for six
major diabetes drug classes: insulin, sulfonylureas (SUs), thiazolidinediones (TZDs),
glucagon-like peptide-1 receptor agonists, dipeptidyl peptidase-4 inhibitors, and
sodium glucose cotransporter 2 inhibitors. This article, an outgrowth of the forum,
summarizes well-delineated and theoretical safety concerns related to these drug
classes, as well as the panelists’ opinions regarding their best use in patients with
type 2 diabetes. All of the options appear to have reasonably wide safety margins
when used appropriately. Those about which we know the mostdmetformin, SUs,
insulin, and perhaps now also TZDsdare efficacious in most patients and can be
placed into a basic initial algorithm. However, these agents leave some clinical needs
unmet. Selectingnext steps is amore formidableprocess involving neweragents that
are understood less well and for which there are unresolved questions regarding risk
versus benefit in certain populations. Choosing a specific agent is not as important as
implementing some form of early intervention and advancing rapidly to some form
of combination therapy as needed. When all options are relatively safe given the
benefits they confer, therapeutic decision making must rely on a personalized ap-
proach, taking into account patients’ clinical circumstances, phenotype, pathophys-
iological defects, preferences, abilities, and costs.
Today, there are more therapy options for managing type 2 diabetes than ever
before. Primary care and specialty clinicians and the patients they advise benefit
from having a wide range of interventions from which to choose in developing
diabetes management plans. However, this abundance also means that therapeutic
decision making has become increasingly challenging.
Recommendations published in 2012 by the American Diabetes Association (ADA)
and the European Association for the Study of Diabetes (EASD) (1) set forth a flexible
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treatment algorithm that begins, in most
cases, with lifestyle intervention andmet-
formin therapy. The algorithm progresses
to dual and triple therapy and, through a
patient-centered, individualized decision-
making process, to numerous and in-
creasingly complex combination therapy
options involving various classes of oral
and injectable medications. Recent con-
sensus guidelines from the American As-
sociation of Clinical Endocrinologists
(AACE) (2) described a similar algorithm
with rather aggressive A1C criteria for
initiating dual therapy. Both sets of
guidelines encourage consideration of
individual patients’ characteristics,
needs, and preferences.
This trend toward a more personal-
ized approach has focused attention
on the relative differences among avail-
able pharmacological agents in terms
of mechanisms of action, efficacy, and,
perhaps most important, safety. It is
on the basis of these differences that
treatment decisions for individual pa-
tients must be made. To further this dis-
cussion, we convened a nine-member
Diabetes Care Editors’ Expert Forum in
June 2013 to review the latest safety
evidence for six of the major diabetes
drug classesdinsulin, sulfonylureas
(SUs), thiazolidinediones (TZDs), glucagon-
like peptide-1 (GLP-1) receptor agonists,
dipeptidyl peptidase-4 (DPP-4) inhibitors,
and sodium glucose cotransporter 2
(SGLT-2) inhibitors (Videos 1 and 2, avail-
able at http://dx.doi.org/10.2337/
dc14-1395). This article summarizes
both well-characterized and theoretical
safety concerns related to thesedrug clas-
ses, aswell as our opinions regarding their
most efficacious use in patients with type
2 diabetes. We also provide, in Table 1, a
list of key topics for discussion with pa-
tients who may be considering the use of
agents in these classes.
SAFETY CONSIDERATIONS FOR THE
MAJOR DRUG CLASSES FOR TYPE 2
DIABETES
Insulin
Since its discovery in 1922, insulin has
been the essential treatment for type 1
diabetes and has become an important
keystone of treatment for type 2 diabe-
tes. Given the natural history of type 2
diabetes and the fact that insulin secre-
tory deficits progress throughout the
disease process, insulin is eventually re-
quired in the majority of cases. With
numerous insulin formulations now
available, one can design a therapy re-
gimen that closely mimics normal physi-
ology, offering efficacy while minimizing
hypoglycemia (3). However, insulin of-
ten is initiated very late in the course
of the disease (4).
Documented Safety Issues
Several concerns, both real and per-
ceived, may explain why insulin initiation
is often delayed. These include increased
risks for hypoglycemia andweight gain, as
well as the misperception held by some
that insulin may not be appropriate in a
disease not considered to be character-
ized by insulin deficiency, but rather by
hyperinsulinemia and insulin resistance.
Although hypoglycemia is the single
greatest drawback to insulin therapy,
the development of basal insulin ana-
logs has provided better opportunities
for its safe and effective implementa-
tion. A 2007 Cochrane analysis (5) re-
viewed data on the long-acting insulin
analog glargine and revealed significant
reductions of ;15% in the overall risk
for hypoglycemia and ;35% in the risk
for nocturnal hypoglycemia compared
with NPH insulin in patients with type
2 diabetes. This risk reduction appears
to be limited to the long-acting analog
formulations, however. A 2006 Cochrane
analysis (6) comparing data on rapid-
acting insulin analogs to those of regu-
lar human insulin in type 2 diabetes
found little difference in hypoglycemia
rates (weighted mean difference in over-
all hypoglycemic episodes/patient/
month of –0.2 [95% CI –0.5 to 0.1] for
analogs vs. regular insulin).
The risk for hypoglycemia also ap-
pears to differ based on the type of in-
sulin regimen used. For example, in the
4-T (Treating To Target in Type 2 Diabe-
tes) study (7), the use of basal analog
insulin was associated with fewer hypo-
glycemic events, whereas premixed bi-
phasic insulin formulations carried a
greater hypoglycemia risk, and the risk
was higher still in regimens involving
prandial analog insulin (median events/
patient/year of 1.7, 3.0, and 5.7, respec-
tively; P , 0.001 for the overall compar-
ison). Of interest, the different insulin
formulations are also associated with dif-
ferent risks for weight gain, with greater
gains resulting from the use of prandial
analog and premixed formulations and
less from basal insulin (7).
Potential Safety Issues
Although concerning to patients and
clinicians, the risks for hypoglycemia
and weight gain may be managed
through careful selection of insulin for-
mulations and regimens, attention to
patients’ clinical circumstances, and ap-
propriate patient education regarding
hypoglycemia prevention, detection,
and treatment, as well as the impor-
tance of lifestyle measures to control
weight.
Does insulin use pose a potentially
more serious concern with regard to
the atherogenic effects of chronic hy-
perinsulinemia in type 2 diabetes?
Most of the data on this issue have
come from post hoc analyses suggest-
ing that insulin may increase the risk
for cardiovascular events (8). However,
well-designed, prospective studiesd
most notably the ORIGIN (Outcome
Reduction With Initial Glargine Inter-
vention) trial (9), in which patients
with short-duration type 2 diabetes
and a high risk for cardiovascular dis-
ease (CVD) were treated with basal in-
sulin for .6 yearsdhave found that
insulin therapy had a neutral effect on
cardiovascular events compared with
routine comparator therapies. The risk
for severe hypoglycemia was relatively
low in glargine-treated subjects but still
greater than in the standard group (1.0
vs. 0.3% per year). Interestingly, the risk
for cardiovascular events was increased
in subjects with severe hypoglycemia
and not in those withmild hypoglycemia
regardless of treatment, but it was sig-
nificantly higher in the standard group
than in the glargine group (10).
The ORIGIN trial also helped to ease
another concern: the potential of long-
acting insulin analogs to increase pa-
tients’ risks for developing various forms
of cancer. Although previous studies
(11–13) reported increased cancer rates
among patients using long-acting insu-
lin, ORIGIN investigators found a neutral
effect of glargine on the risk for neopla-
sia, both overall and in terms of several
specific types of cancer.
In the ORIGIN trial, insulin use in peo-
ple with prediabetic hyperglycemia was
associated with reduced or delayed con-
version to overt diabetic hyperglycemia.
Along with this observation, evidence is
accumulating in support of the possibil-
ity of inducing remission of new-onset
type 2 diabetes through early insulin
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Table 1—Topics for discussion with patients (or as part of structured education programs) regarding potential adverse
reactions to glucose-lowering pharmacotherapy
Problems to address Topics for patient education
Insulin Late initiation of insulin treatment Overcoming resistance to insulin therapy
Careful balance of risks and benefits
Necessity for glucose monitoring Individualized self-monitoring plan (how frequently, what
times of day)
Dependence on integrity of insulin preparation and




Hypoglycemia Prevention of conditions potentially leading to
hypoglycemia
Early recognition of hypoglycemia
Self-treatment of hypoglycemia
Treatment of hypoglycemia through proxies
Weight gain Nutritional strategies to prevent weight gain or reduce
body weight
Alternatives to progression to multiple injections
after failing “bedtime” insulin treatment
Instead of meal-time insulin:
Add a GLP-1 receptor agonist
Add a TZD
Add an SGLT-2 inhibitor
SUs Hypoglycemia See hypoglycemia recommendations for insulin
Risk for hypoglycemia recurrence after initially successful
treatment; necessity for continued surveillance
Weight gain See weight gain recommendations for insulin
Concerns regarding cardiovascular risks Balanced discussion of current evidence (pro: observational
studies; con: UKPDS, ADVANCE)
TZDs Advantage of best record for durability Discussion of the concept of durability and its importance
for the individual patient
Advantage of potential cardiovascular benefit Discussion of cardiovascular outcomes with pioglitazone
Weight gain See weight gain recommendations for insulin
Risk for fluid retention and related adverse effects




Increased risk for fractures Discussion of individual susceptibility for fractures
Preventive measures
Appropriate dosing
Increased risk for bladder cancer Discussion of this as an unresolved issue
Information about the potential quantitative impact
Screening and surveillance measures
Incretin-based
therapies
Nausea, vomiting, diarrhea (GLP-1 receptor agonists only) Rare and transient nature
Possibility that drug needs to be withdrawn in aminority of
patients
Potential pharmacotherapy for side effects
Injection site reactions and nodules (GLP-1 receptor
agonists only)
Information about nature of this side effect
(immunological responses potentially related to
antibody formation)
Possibility that repeated episodes may suggest the need to
discontinue this treatment
Increased risk for hospitalization for heart failure (?) Information on recognition of symptoms
Clinical significance of study findings are undetermined
Caution for those at high risk
Increased risk for acute pancreatitis (?) Discussion of this as an unresolved issue
Early signs and symptoms of pancreatitis, behavioral
advice in such a case (seek medical advice, discontinue
treatment)
Advice for alternative treatment in the case of past
episodes of pancreatitis
Increased risk for medullary thyroid carcinoma (?) Information about the low likelihood in the face of the
rarity of this disease
Advice for alternative treatment in the case of a personal
or family history or with a given genetic background
(multiple endocrine neoplasia syndrome type 2)
Continued on p. 2650
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therapy. A recent meta-analysis (14)
synthesized data from studies of short-
term intensive insulin therapy in newly
diagnosed patients to determine its ef-
fects on insulin sensitivity and b-cell
dysfunction, the two main pathophysio-
logical defects responsible for hypergly-
cemia and diabetes progression. This
analysis found that early introduction
of insulin was associated with an im-
provement in both conditions.
Thus, although insulin is not without
risks, its use in appropriate patients at
the appropriate time does offer signifi-
cant benefit. It not only improves short-
term glycemic control, but also may be a
viable strategy for altering the course
of the disease, enabling patients to
achieve a state of remission during which
normoglycemia can be sustained for
some time without further treatment.
Insulin: Rethinking When and How
Because most patients with type 2 dia-
betes continue to secrete some amount
of endogenous insulin even in the late
stages of the disease, initial insulin ther-
apy usually involves a basal-only regi-
men aimed at suppressing overnight
hepatic glucose production, thereby
lowering glucose levels during sleep
and betweenmeals. In this regard, prev-
alent fasting hyperglycemia is perhaps
the best indicator of the need for basal
insulin, even when it occurs early in the
disease. Other situations, such as inter-
mittent comorbidities, surgical inter-
ventions, and pregnancy, also may call
for insulin initiation, at least in the short
term.
Newly diagnosed patients usually be-
gin diabetes treatment with metformin
monotherapy (or monotherapy with an
SU or incretin-based agent) and prog-
ress to some form of combination oral
agent therapy before starting basal
insulin. However, adding basal insulin
immediately after metformin may be
appropriate in some cases; likewise,
forgoing insulin in favor of a second or
third oral agent may be reasonable
(although likely more costly) for some
patients. A notable exception to the
standard treatment algorithm is for
newly diagnosed patients with extreme-
ly poor glycemic control and a high A1C,
for whom immediate insulin therapy
is recommended to ameliorate glucose
toxicity and related symptoms (1,2).
Such patients often can substantially re-
duce or discontinue insulin in favor of oral
agents after glycemic control stabilizes.
SUs
As the first available oral agents for glu-
cose lowering, SUs have a 60-year re-
cord of use, second only to that of
insulin. Thus, there is a substantial da-
tabase from which to draw conclu-
sions regarding their efficacy and
safety (15–19). These agents stimu-
late endogenous insulin release in a
nonglucose-mediated manner by clos-
ing ATP-sensitive potassium channels
located on pancreatic b-cells (20).
They are widely used in the U.S. and
around the world, accounting for ;25%
of newly initiated oral therapies for di-
abetes (21). In the U.S., they are consid-
ered one of several second-line options
after metformin for most people with
type 2 diabetes and a viable first-line al-
ternative for patients who cannot take
metformin (1,2).
Drugs in this class can be divided into
two groups: historical agents that are no
longerwidely used (including carbutamide,
acetohexamide, chlorpropamide, tol-
butamide, and tolazamide) and cur-
rently used agents (including glyburide
[also known as glibenclamide], gliclazide,
glipizide, and glimepiride). Most of the
historical SUs have adverse effects that
have limited their use (22–24), and it
has been suggested that the routine
use of glyburide should also be re-
stricted (25). Glyburide interferes with
cardiac ischemic preconditioning (26);
compared with the other modern SUs,
it may be associated with higher mor-
tality rates when coadministered with
metformin (27) and after hospitaliza-
tion for myocardial infarction (MI)
(22), and it causes more hypoglycemia
(28).
To our way of thinking, the ideal anti-
hyperglycemic agent would be easy to
administer, unlikely to cause symptom-
atic side effects that pose barriers to
adherence, inexpensive, reliably effica-
cious, and safe. By such standards, it can
be argued that the remaining modern
SUs do well (although they do leave
some clinical needs unmet). Glimepiride
and extended-release preparations of
glipizide and gliclazide can be given
once daily and rarely cause symptomatic
side effects other than hypoglycemia.
They appear to be as effective as or
more effective than other oral agents
in terms of A1C reduction, life expec-
tancy, and quality-adjusted life-years
(29,30). And SUs are remarkably inex-
pensive compared with newer oral
agents (31).
Table 1—Continued
Problems to address Topics for patient education
SGLT-2 inhibitors Genital infections (Candida and other fungi) Signs and symptoms
Preventive measures (hygiene)
Consider other treatments after repeated occurrence
Urinary tract infections (bacterial) Signs and symptoms (including those of more severe,
ascending infections [urosepsis])
Preventive measures (hygiene)
Consider other treatments after repeated occurrence
Negative fluid balance Information about potential consequences (too great
a drop in blood pressure, impairment of kidney function)
Elevated LDL cholesterol Impact on overall cardiovascular risk
Treatment options (statins, target values, careful dose-
finding)
Risk for bladder cancer Discussion of this as an unresolved issue
Information about the potential quantitative impact
Screening and surveillance measures
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Documented Safety Issues
Hypoglycemia and weight gain are the
main well-documented safety issues re-
lated to SUs (19,32). Starting an SU typ-
ically leads to a weight gain of ;2 kg
depending on prior A1C level and hypo-
glycemia rates two to three times higher
than with other agents (29). Although
significant, these risks usually can be
managed with appropriate patient se-
lection, attention to dosing, and ade-
quate patient education. Patients with
compromised renal functioning are par-
ticularly susceptible to hypoglycemia
from SUs; hence, their use in this popu-
lation should be avoided. Allergy and
other idiosyncratic effects are rare.
Potential Safety Issues
Concerns about the potential effects of
SUs on cardiovascular risk, possibly re-
lated to interference with cardiac ische-
mic preconditioning (33), have existed
since at least 1970, with the controversial
results from the University Group Diabe-
tes Program (UGDP) (34) suggesting that
tolbutamide might be associated with an
increased risk for cardiovascular mortal-
ity. Attention to this issue subsided some-
what with the emergence of other SUs
(35), but findings from retrospective anal-
yses of associations between oral diabe-
tes drugs and cardiovascular outcomes
have been inconsistent (36–40).
Recent trials and analyses have been
more reassuring. In 1998, the UK Pro-
spective Diabetes Study (UKPDS) group
(41) reported no difference in the rates
of MI or diabetes-related death among
subjects receiving chlorpropamide, gly-
buride, or insulin. Researchers in the
ADVANCE (Action in Diabetes and Vas-
cular Disease: Preterax and Diamicron
MR Controlled Evaluation) trial (42)
reached a similar conclusion in 2008,
reporting no significant differences
between intensive glucose control in-
volving gliclazide and other drugs as re-
quired and conventional care in major
macrovascular events, death from car-
diovascular causes, or death from any
cause. The RECORD (Rosiglitazone Eval-
uated for Cardiovascular Outcomes in
Oral Agent Combination Therapy for
Type 2 Diabetes) study (43) similarly
found no significant differences in the
risk for cardiovascular events among
combination therapy with rosiglitazone
and metformin, rosiglitazone and SU,
or metformin and SU. Although not
designed to evaluate cardiovascular out-
comes, the ADOPT (A Diabetes Outcome
Progression Trial) study (44), which
compared the durability of effective-
ness of monotherapy with metformin,
rosiglitazone, or glyburide, reportednom-
inally lower rates of cardiovascular events
in patients taking glyburide than in those
taking either rosiglitazone or metformin.
A 2013 meta-analysis (45) of 62 trials
reporting major cardiovascular events
with SUs versus various comparators
has provided perhaps the best synthesis
of data to date. This analysis found an
overall odds ratio (OR) for major car-
diovascular events with SU treatment
versus comparators of 1.08 (95% CI
0.86–1.36), thus detecting no signal for
cardiovascular risk. However, the au-
thors urged cautious interpretation of
their results given limitations of trial
quality and potential underreporting of
information on cardiovascular events
and mortality.
Further evidence in support of SUs
comes from modern epidemiological
studies such as a recent retrospective
health system database analysis from
Alberta, Canada (46), which sought to
determine whether patients taking SUs
at the time of acute coronary syndrome
were more likely to have poor out-
comes. Its results indicated an adjusted
OR for using versus not using an SU of
1.06 (95% CI 0.89–1.26). One possible
explanation for the lack of an apparent
association between the use of SUs and
higher cardiovascular risk in recent
studies is the decline in the use of gly-
buride in favor of SUs with a lower pro-
pensity to cause hypoglycemia and
without significant effects on ischemic
preconditioning.
SUs: a Proven and Still Valuable Option
As new drug classes have been intro-
duced, promotional efforts have sug-
gested that SUs are an outmoded class
to be replaced by newer agents. How-
ever, we do clearly know the efficacy of
these agents, just as we are aware of
their limitations of hypoglycemia and
weight gain. Objectively, one could ar-
gue that, given the wealth of clinical ex-
perience, new safety concerns are not
likely to emerge. Although poor durabil-
ity of effectiveness has been a major
criticism, participants assigned to stan-
dard therapy in the ORIGIN trial, treated
mainly with metformin and an SU,
maintained glycemic control (average
A1C 6.5%) for 6 years (9). SUs also offer
the advantages of ease of administra-
tion, good tolerability, and low cost.
Still, clinicians prescribing SUs must
take care to help patients avoid hypogly-
cemia. Appropriate patient selection is
important, especially when considering
SUs for patients who are elderly or frail,
have a history of hypoglycemia or hypo-
glycemia unawareness, or have renal
dysfunction or other conditions or co-
morbidities likely to place them at high
risk. Glyburide should rarely be consid-
ered because of its greater tendency to
cause hypoglycemia.
TZDs
TZDs have been a source of both enthu-
siasm and controversy since troglita-
zone, the first agent in the class, was
approved in the U.S. in 1997 to address
insulin resistance. This ushered in a new
paradigm of treatment and was fol-
lowed by rosiglitazone and pioglitazone
in 1999 (47). TZDs are synthetic ligands
that activate PPAR-g nuclear receptors
in adipose tissue, skeletal muscle, and
the liver (48). They act primarily to im-
prove insulin sensitivity and reduce he-
patic glucose production and are, to
date, the only class of agents specifically
targeting insulin resistance, which is one
of the primary defects in type 2 diabetes
and other insulin-resistant states such
as impaired glucose tolerance and poly-
cystic ovary syndrome.
The main appeal of TZDs is their du-
rability of effect in lowering A1C (49–
52), as well as their potential to alter
the natural progression of diabetes in a
way that cannot be achieved with other
oral agents (43,44). However, seeking
this goal would necessitate initiating
TZD therapy early in the course of the
disease, making consideration of safety
issues surrounding this drug class partic-
ularly important.
Documented Safety Issues
Troglitazone was withdrawn from the
U.S. market in 2000 because of concerns
regarding hepatotoxicity (53). In the
mid-2000s, several articles were pub-
lished suggesting that rosiglitazone
was associated with excess cardiovascu-
lar events, specifically MIs. As a result,
the use of rosiglitazone was tightly re-
stricted in 2011 (54). However, the
RECORD study (43), reported in 2009,
had documented no increased risk for
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cardiac adverse events. A recent U.S.
Food and Drug Administration (FDA)–
mandated readjudication of the RECORD
findings (55), which confirmed no in-
crease in overall cardiovascular risk with
rosiglitazone, prompted the FDA to lift its
restrictions on this agent but maintain
specific warnings related to increased
risks for congestive heart failure and
bone fractures (56).
For now, pioglitazone remains the
most widely used TZD, and research sug-
gests that its safety profile is less con-
troversial than other agents in this class.
Although the PROactive (Prospective
Pioglitazone Clinical Trial in Macrovas-
cular Events) trial (57), a cardiovascular
outcomes randomized controlled trial
(RCT), failed to meet statistical sig-
nificance for a primary end point com-
posed of numerous macrovascular
outcomes, a subanalysis of a secondary
end point encompassing MI, stroke, and
cardiovascular death found a modest
but statistically significant reduction.
Other well-recognized concerns re-
lated to the TZDs include weight gain,
fluid retention leading in some cases to
edema or congestive heart failure, and
increased risk for bone fractures, often
at peripheral sites, which is perhaps one
of the greatest concerns with this class
(58,59). Mechanistic studies have
shown that there is a theoretical possi-
bility that TZDs could alter the differen-
tiation of mesenchymal stem cells
toward the formation of fat and away
from the formation of bone. Both RCTs
(60) and pharmacoepidemiological anal-
yses (61) have revealed an increased
absolute risk for bone fractures of ;1%
in men and 3% in women.
Fluid retention usually can be man-
aged through patient counseling and
careful patient selection and safely miti-
gated with thiazide diuretics. Although
the potential for heart failure has been
an important safety consideration, indi-
vidual studies and meta-analyses sug-
gest that there is a small increase in
the absolute risk for heart failure requir-
ing hospitalization but no increase in
fatal heart failure (62).
TZDs also have been associated with
an increased incidence of macular
edema in retrospective, observational
studies with an approximately twofold
increased risk (63). However, this has
not been consistently observed in RCTs
(64). Certainly, patients treated with
TZDs should have annual dilated fundu-
scopic exams and should seek attention
for more than transient visual changes.
Other common TZD side effects in-
clude anemia, rare instances of in-
creased creatine phosphokinase (but
not serious myositis), variable changes
in lipids, and possible hepatic effects.
The latter necessitate the avoidance of
these agents in patients with substantial
liver disease, although some studies
have suggested that TZDs actually may
be beneficial in the setting of fatty liver
disease (58,59,65); furthermore, be-
cause TZDs are not excreted through
the kidney, they are potentially useful
for patients with chronic kidney disease.
Finally, because the risk for hypoglyce-
mia may be increased when TZDs are
used in combination with insulin or in-
sulin secretagogues, doses of these lat-
ter agents should be reduced in such
circumstances.
Potential Safety Issues
As accumulating evidence lessens con-
cern about cardiovascular risk, the main
remaining potential, but as yet un-
proven, safety issue related to TZDs
is a possible link to increased rates of
bladder cancer with pioglitazone. This
issue arose because of imbalances de-
tected in the development of bladder
tumors in preclinical animal studies of
pioglitazone and of experimental drugs
with dual PPAR-g and PPAR-a activity
(58,66). Imbalances in the number of blad-
der cancer cases have also been reported
in some RCTs, most notably PROactive
(57), which found a nonsignificant in-
crease in bladder tumors in pioglitazone-
treated patients. The most robust
pharmacoepidemiological study to date
(67), which is being conducted at the
request of the FDA, detected no overall
signal for bladder cancer risk at 5 years,
but did suggest a modest increase in risk
only in patients with long exposure to or
on high doses of pioglitazone. However,
in more recent analyses, the statistical
significance of these findings disap-
peared by 8 years of follow-up and the
cancers detected were almost all in an
early stage (68).
Further study will be required to fully
elucidate this potential risk. For now,
prescribing information for pioglitazone
suggests that it not be used in patients
with a history of bladder cancer and that
all patients should be instructed to seek
medical attention for any urinary symp-
toms that may develop (58).
TZDs: Proceed With Caution
Until the issues enumerated above are
put to rest, TZDs most likely will be con-
sidered as third- or fourth-line options
after combinations of other agents. In
such situations, the balance of benefit
to risk is still quite strongly in favor of
these drugs.
Incretin-Based Therapies: GLP-1
Receptor Agonists and DPP-4 Inhibitors
GLP-1 is a gut-derived incretin hormone
that stimulates insulin secretion in a
glucose-dependent manner, suppresses
glucagon secretion similarly, slows gas-
tric emptying, reduces appetite, and
may expand b-cell mass (69). The devel-
opment of two drug classes that act
through stimulation of GLP-1 receptors
to enhance incretin actiondGLP-1 re-
ceptor agonists (incretin mimetics) and
DPP-4 inhibitors (incretin enhancers)d
has been an important advancement in
the pharmacological treatment of type 2
diabetes (70) because these agents ef-
fectively control glycemia without caus-
ing hypoglycemia or weight gain.
GLP-1 receptor agonists are peptides
that mimic native GLP-1, binding to its
receptors to elicit the same effects, but
at much higher pharmacological levels
than the physiological profiles. Agents
in the class currently available in the
U.S. include exenatide twice daily, exena-
tide once weekly (QW), liraglutide once
daily, and albiglutide QW, all of which
are administered through subcutaneous
injection. Other agents in development
include dulaglutide QW and semaglutide
QW, as well as lixisenatide once daily,
which is available in Europe.
DPP-4 inhibitors act to suppress the
proteolytic enzyme (i.e., DPP-4) that
normally degrades endogenous GLP-1
and thereby increase the concentration
of intact, biologically active GLP-1 and
augment its interaction with receptors.
DPP-4 inhibitors available globally and in
the U.S. include alogliptin, linagliptin,
saxagliptin, and sitagliptin. Vildagliptin is
also globally available except in the U.S.,
and other DPP-4 inhibitors are available
in Japan. All are administered orally.
The mechanisms of incretin-based
therapies, and the clinical trials demon-
strating the efficacy and safety profiles
on which our understanding of them is
based, have been extensively reviewed
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elsewhere (70–73). Briefly, agents in
both classes have been shown to lower,
to varying degrees, A1C, fasting plasma
glucose, and postprandial glucose.
Whereas GLP-1 receptor agonists also
slow the rate of gastric emptying in dif-
ferent degrees based on their pharma-
cokinetic profiles and can cause a sense
of satiety leading to reduced food intake
and moderate weight loss, DPP-4 inhib-
itors do not slow the rate of gastric emp-
tying and are weight-neutral. Neither
type of therapy increases the risk for
hypoglycemia except when associ-
ated with SUs or insulin. Clinical trials
of agents in both classes also have
shown improvements in some surro-
gate markers of pancreatic b-cell func-
tion in type 2 diabetes. Both also may
yield modest improvement in lipid pro-
files and systolic blood pressure levels,
although short-term studies have shown
only neutrality for cardiovascular events
(74,75).
Current guidelines (1,76) recommend
both types of incretin-based therapies
for use as monotherapy (mostly in pa-
tients for whommetformin is not an op-
tion) and in combination with other
agents (most often metformin) if, for
example, treatment priorities include
reducing the risk for hypoglycemia and
controlling body weight.
Documented Safety Issues
The most common treatment-related
adverse effects of GLP-1 receptor ago-
nists are gastrointestinal in nature and
include nausea, vomiting, and diarrhea,
which are usually mild and tend to sub-
side over time but in some patients may
be intermittent and lead to eventual dis-
continuation (77,78). A dose-titration
strategy has been found to reduce the
incidence of nausea (79), but ,5% of
patients in clinical trials need to discon-
tinue treatment because of such side
effects (77,78). However, discontinua-
tion rates in clinical practice are greater,
mainly as a result of gastrointestinal in-
tolerance without the type of support
system typically available in clinical tri-
als and perhaps disenchantment when
these agents are initiated mainly in
hopes of achieving weight loss.
Other documented but infrequent
concerns with GLP-1 receptor agonists
include injection site reactions (80) and,
particularly with exenatide QW, the de-
velopment of transient small nodules
around injection sites related to the vis-
cous nature of the formulation (81).
DPP-4 inhibitors have been shown to
have a very good safety and tolerability
profile similar to that of placebo (72,82).
Unlike GLP-1 receptor agonists, DPP-4
inhibitors are not associated with gas-
trointestinal adverse events. Early signs
that their use may be associated with
more upper respiratory tract and uri-
nary tract infections have not been
confirmed (82,83). Evidence to date sug-
gests that DPP-4 inhibitors do not af-
fect cardiovascular risk with ;2 years
of exposure in high-risk populations
(82).
Severe hypoglycemia has not been
observed in trials of any incretin-based
monotherapy (77,84–90), but mild to
moderate hypoglycemia has occurred
in 0–12% of patients, depending on
the agent studied (77,84–86,88–91). A
higher hypoglycemia rate has been
documented when such agents are
used in combination with SUs or insulin
(78,92–99); hence, decreasing the dos-
age of these concomitant agents is rec-
ommended.
Potential Safety Issues
Low-frequency findings of as yet un-
known clinical significance have raised
additional questions regarding the
long-term safety of incretin-based ther-
apies (100,101). The results of ongoing
prospective studies will help to address
these issues.
Heart Failure. The SAVOR (Saxagliptin As-
sessment of Vascular Outcomes Re-
corded in Patients with Diabetes Mellitus)
study (74) found an increased rate of
hospitalization for heart failure com-
pared with standard care, although
overall cardiovascular events, including
heart failure, did not increase. Data
from the EXAMINE (Examination of
Cardiovascular Outcomes with Alogliptin
versus Standard of Care in Patients
With Type 2 Diabetes Mellitus and
Acute Coronary Syndrome) trial (75)
were consistent with this observation
but even less robust. Whether the ef-
fect is real and, if so, the extent of its
clinical significance remains uncertain
pending the completion of other stud-
ies (102,103). In the meantime, caution
seems indicated in people with or at
high risk for heart failure.
Acute Pancreatitis. Cases of pancreatitis
have been reported in animals (104–
107) and humans (108) treated with
GLP-1 receptor agonists or DPP-4 inhib-
itors. The question of whether such
casesmay potentially be caused by treat-
ment with incretin-based therapies re-
mains unanswered.
Animal studies have been inconsis-
tent, although most preclinical models
cannot reflect the human pancreatitis
model. Some have described histologi-
cal changes consistent with damage to
the exocrine pancreas with exenatide
(104,105) and sitagliptin (107), but not
with liraglutide (106). Other studies in
mice have documented improvement
of experimentally induced acute pancre-
atitis with exenatide (109) and an anti-
inflammatory cytokine response with
liraglutide (110).
Small imbalances in the number of
cases of acute pancreatitis reported in
several of the clinical development pro-
grams of incretin-based therapies led
the FDA to require a warning regarding
the possibility of developing acute pan-
creatitis and a recommendation to avoid
these agents in people with a history
of pancreatitis (111). Retrospective, ob-
servational studies of acute pancreatitis
from incretin-based therapies have
found ORs near 1, suggesting no in-
creased risk. However, these ratios
have wide CIs due to the small number
of cases (112–116). Furthermore, these
types of reports, obtained from insur-
ance claims data, electronic medical re-
cords, or prescription databases, are not
prospectively designed to answer spe-
cific questions regarding the safety of
therapeutic interventions. Thus, any
findings can only be regarded as either
hypothesis-generating or merely sug-
gestive, but certainly cannot be viewed
as definitive. A single study reporting
that patients taking exenatide or sita-
gliptin had a tenfold higher likelihood
of developing pancreatitis was based
on data from the FDA Adverse Event Re-
porting System, which is susceptible to
reporting bias (117). A case-control
study looking at the rate of hospitaliza-
tion for pancreatitis found a higher OR
among patients taking “incretin-based
therapies,” but yielded no significant
findings for either GLP-1 receptor ago-
nist or DPP-4 inhibitor therapy when an-
alyzed separately (118). The possibility
exists that a combination of gastrointes-
tinal symptoms and spontaneously ele-
vated lipase activity (as is typical for a
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type 2 diabetic population [119]) were
misdiagnosed as pancreatitis in at least
some of these cases.
As recently recommended in this
journal (120), patient-level safety data
from the multiple ongoing, cardiovascu-
lar outcomes RCTs of incretin-based
therapies should be combined to pro-
vide sufficient statistical power for
more conclusive meta-analyses. Such
efforts should yield more definitive an-
swers regarding pancreatitis and incre-
tin-based therapies in the coming years.
Chronic Pancreatitis and Pancreatic
Cancer. Concerns have been raised regard-
ing the potential role of incretin-based
therapies in inducing chronic pancreati-
tis, which, in the long run, could promote
preneoplastic lesions, thus raising the
risk for pancreatic cancer (101).Whereas
some animal studies have shown histo-
logical changes indicative of chronic pan-
creatitis with exenatide (104,105,107),
a study of liraglutide noted pancreatitis
as a rare finding unrelated to dose and
with similar numbers in placebo-treated
rats, mice, and monkeys (106). Recently
reported tissue analysis from organ do-
nors who had type 2 diabetes and took
incretin-based agents found pancreatic
abnormalities; these reports, and pub-
lished reviews of them, included com-
ments on methodological issues, as
well as preexisting conditions that may
have predisposed to these findings
(121–123).
To date, there have been no reported
cases of clinically identifiable chronic
pancreatitis or pancreatic cancer arising
after initiation of incretin-based thera-
pies. However, given the relatively short
time these agents have been in use and
the typically slow development of pan-
creatic carcinomas (124), it is too early
to know.
Medullary Thyroid Carcinoma. One study
has shown that exposure to long-acting
GLP-1 receptor agonists increased thy-
roid C-cell hyperplasia, adenomas, and
medullary thyroid carcinomas in mice
and rats (125). It is important to note,
however, that such abnormalities also
occur spontaneously in these species,
especially in male rats, in which medul-
lary thyroid carcinoma also developed
with placebo. Rodent C-cell lines produce
cyclic AMP and secrete calcitonin. Sim-
ilar human cell lines do not show such
effects (125), and long-term high-dose
GLP-1 receptor agonist treatment in
type 2 diabetic or obese humans did not
elicit elevations in plasma calcitonin
(126). Rodent C cells have considerably
more GLP-1 receptors than their human
counterparts (125). Thus, GLP-1 stimula-
tion probably does not provoke prolifer-
ative responses in human C cells, and no
such cases have been reported. Medul-
lary thyroid carcinoma is extremely rare
in humans (127).
Incretins: Safety Signals Still Require
Vigilance
Although the known and anticipated
benefits of incretin-based therapies ap-
pear to be substantial, the potential
risks for serious rare events remain con-
troversial and in need of further elu-
cidation through long-term studies.
Safety concerns related to alterations
of the exocrine pancreas and thyroid,
while deserving of further study, are
not yet firmly substantiated. An excel-
lent debate on this topic was published
in a previous issue of Diabetes Care
(100,101). The FDA and the European
Medicines Agency (EMA) carefully scru-
tinized preclinical and clinical data on
this topic and recently came to a similar
conclusion that no changes in recom-
mendations are necessary until more
firm data are available (128).
SGLT-2 Inhibitors
SGLT-2 inhibitors are the newest class of
medications and, as such, have the least
available research and clinical data re-
garding their effective use and adverse
effects. The mechanisms and efficacy of
these agents have been reviewed else-
where (129–131). The main advantage
of SGLT-2 inhibitors is a completely dif-
ferent mechanism of action; they work
primarily to lower the renal threshold to
glucose, leading to increased glucose
excretion and decreased plasma glucose
levels. Because this mode of action is
not dependent on insulin secretion,
agents in this class can be considered for
use in combination with other glucose-
lowering agents throughout the course
of type 2 diabetes and potentially can
be a useful add-on therapy to insulin in
type 1 diabetes.
The efficacy of SGLT-2 inhibitors ap-
pears to be similar to that of other anti-
hyperglycemic agents; they significantly
reduce fasting and postprandial glucose
levels, leading to A1C reductions of
;0.5–1.0%. These agents also induce
mild osmotic diuresis and a net loss of
calories, yielding a slight reduction in
blood pressure and a net weight loss.
Because SGLT-2 inhibitors have no ef-
fects on glucose-dependent endoge-
nous insulin secretion and do not
completely halt glucose reabsorption,
they carry a low risk for severe hypogly-
cemia (132–134).
Two SGLT-2 inhibitorsdcanagliflozin
and dapagliflozindare currently avail-
able in the U.S. and elsewhere; both
are administered in once-daily oral tab-
lets (135,136).
Empagliflozin was recently approved
by the EMA, and several other SGLT-2
inhibitors are available in Japan.
Documented Safety Issues
Genital mycotic infections and urinary
tract infections have been the most
commonly reported adverse events as-
sociated with SGLT-2 inhibition to date
(137–140). These occurrences are usu-
ally mild to moderate and responsive to
treatment, and they rarely result in dis-
continuation of therapy (141,142). Stud-
ies have also shown that some adverse
events related to osmotic diuresis (e.g.,
polyuria) are greater with SGLT-2 inhib-
itors than with placebo. In addition,
there have been some unusual labora-
tory parameters, such as changes in
hemoglobin, plasma magnesium, and
blood urea nitrogen levels and, interest-
ingly, increases in both HDL and LDL cho-
lesterol. Furthermore, studies have
documented some volume-related ad-
verse events, such as hypotension and
postural dizziness, which require further
study and could have implications for
the use of these agents, particularly in
the elderly population (141,142). Mild
hypoglycemia has been documented
with concurrent use of SGLT-2 inhibitors
and insulin or insulin secretagogues
(134,143). Hence, reductions in the dos-
ages of such agents are recommended
when used in conjunction with SGLT-2
inhibitors (135,136).
Potential Safety Issues
Although canagliflozin was the first
SGLT-2 inhibitor to receive FDA ap-
proval, a similar agent, dapagliflozin,
was approved earlier in Europe and in
the U.S. in 2014 (144). Dapagliflozin’s
safety and effectiveness were evaluated
in 16 clinical trials involving 9,400 patients
with type 2 diabetes taking the agent as
monotherapy or in combination with
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other diabetes pharmacotherapies.
These trials showed improvement in
A1C and found that the most common
side effects were genital fungal infec-
tions and urinary tract infections. How-
ever, because of a numerical imbalance
in bladder cancers seen in dapagliflozin
users, the agent is not recommended
for patients with active bladder cancer
(144). Similar studies of canagliflozin
have not confirmed a bladder cancer
effect; taken together, these studies
have shown no conclusive increased
risks for bladder or breast cancer
(141,142).
Perhaps the greatest concern with
this class of medications is simply the
fact that they have not been studied
long enough to reach definitive conclu-
sions about their long-term safety, ei-
ther in the general population or in
specific subgroups such as the elderly.
Recent studies of volume-related events
in the elderly appeared to indicate that
these agents remain well tolerated and
beneficial even in that high-risk popula-
tion (141), although further study is
needed. Additional research is also
needed to determine the possible ef-
fects of SGLT-2 inhibition on long-term
cardiovascular risk factors and to better
characterize any possible increased risks
for breast or bladder cancer with long-
term use. Large cardiovascular out-
comes trials are under way to satisfy
FDA requirements for cardiovascular
safety; these trials will also provide ad-
ditional data regarding renal safety and
any cancer-related concerns.
SGLT-2 Inhibitors: Much Potential, Many
Unanswered Questions
Through their unique focus on the kid-
ney, SGLT-2 inhibitors have turned a con-
dition once viewed as indicative of poor
glycemic controldglucosuriadinto a
means of achieving decreased plasma
glucose concentrations. These agents
can potentially benefit any patients with
diabetes who have adequate renal func-
tion. In this regard, some studies have
suggested favorable effects in patients
with type 1 diabetes (145,146).
In addition to their favorable effects
on glucose andweight, SGLT-2 inhibitors
also correct the excessive activity of so-
dium reabsorption that is found in type 2
diabetes and that contributes to hy-
pertension, CVD, and other long-term
consequences. In theory, then, these
agents may be particularly useful in pa-
tients who are obese and hypertensive
and who have some degree of estab-
lished CVD.
As with the incretin-based classes,
SGLT-2 inhibitors suffer from a lack
of long-term clinical experience and
research data, leaving numerous unan-
swered questions regarding their long-
term safety. Although themost frequent
adverse effectsdgenital mycotic and
urinary tract infectionsdappear to be
more an issue of patient tolerance
than of safety, we await more data re-
garding possibly significant metabolic
and other side effects, as well as further
elucidation of potential cancer risks.
CONCLUSIONS
Although no pharmacological agent is
without some risk, all of the options dis-
cussed above appear to have wide mar-
gins of safety when used appropriately.
Many years of clinical experience with
the older agents (i.e., insulin, SUs, and
TZDs) and a rapidly growing under-
standing of the newer ones (i.e., GLP-1
receptor agonists, DPP-4 inhibitors, and
SGLT-2 inhibitors) leave us better posi-
tioned than even a few years ago to
help patients achieve and maintain
glycemic control.
The question remaining, then, is how
to determine the most appropriate role
for any given agent in individual pa-
tients. Luckily, the agents and drug
classes about which we have the most
knowledgedmetformin, SUs, insulin,
and perhaps now TZDsdare quite suc-
cessful in most patients and can be
placed into a basic algorithm such as
those recommended by ADA/EASD and
AACE (1,2) and prescribed with some
confidence. Selecting next steps as a
patient’s diabetes progresses remains
a more formidable process involving
newer agents that are understood less
well and for which there are unresolved
questions regarding risk versus benefit in
certain populations.
Shedding more light on the best uses
of these agents will require greater ef-
fort along two fronts. First, additional
evidence is needed regarding which pa-
tients aremost and least likely to benefit
from each pharmacological option. Re-
search studiesmust identify not only the
overall effects of these agents on clinical
outcomes, but also the high- and low-
risk subgroups for each in terms of
physiology, demographics, comorbid-
ities, and other factors. Second, as em-
phasized in the ADA/EASD guidelines
(1), clinicians must solicit and respect
the needs and desires of patients as
partners in the decisionmaking required
to most effectively manage diabetes.
Perhaps the most important message
is that the selection of one agent over
another is not as important as imple-
menting some form of early interven-
tion and advancing rapidly to some
form of combination therapy as needed.
Studies such as ORIGIN (9) have demon-
strated that even the most conventional
regimen can have excellent durability
when started early. The classes of
agents that have been available the lon-
gest are well-proven, cost-effective, and
sensible options for many patients. For
other patients, initiation of an injectable
agent (early insulin in combination with
metformin alone or with another oral
agent or early treatment with a GLP-1
receptor agonist) may be the preferred
choice.
When all options are relatively safe
relative to the benefits they confer,
therapeutic decision making relies
more than ever on a personalized ap-
proach taking into account patients’
clinical circumstances, phenotype, spe-
cific pathophysiological defects, prefer-
ences, abilities, and costs. Regardless of
the specific therapy selected, the over-
arching goal should be to safely achieve
glycemic control at the earliest possible
stage with the least risk for adverse
events, thereby increasing the likeli-
hood of long-term durability of control
and avoidance of complications in the
future.
Acknowledgments. Writing and editing sup-
port services for this article were provided by
Debbie Kendall of Kendall Editorial in Richmond,
VA. The Editorial Committee recognizes the work
of the journal and contributions such as this Expert
Forum would not be possible without the dedi-
cated work and continued support from many
individuals. Specifically, the planning, logistics, and
funding of themeeting and the incredible editorial
supportwould not have beenpossiblewithout the
tireless effort of Chris Kohler and his staff at the
ADA publications office. In addition, the Editorial
Committee would like to thank Lyn Reynolds and
her staff in the ADA editorial office for support in
this regard. The Editorial Committee would also
like to thank Anne Gooch at the Pennington
Biomedical Research Center for her valuable
assistance in helping to organize the Expert
Forum.
care.diabetesjournals.org Cefalu and Associates 2655
Duality of Interest. W.T.C. has served as a
consultant to or received research funding
through his institution from AstraZeneca,
GlaxoSmithKline, Halozyme Therapeutics, Intarcia
Therapeutics, Johnson & Johnson, Lexicon,
MannKind, Novo Nordisk, Nutrition 21, Procter
& Gamble, Sanofi, and Shire Development. J.B.B.
is a consultant to PhaseBio Pharmaceuticals and
has received payments, reimbursement for
travel, and stock options for that effort. He
also has been an investigator and/or consultant
without any direct financial benefit under con-
tracts between his employer (the University of
North Carolina) and the following companies:
Amylin Pharmaceuticals, Andromeda, Astellas,
AstraZeneca, Bayhill Therapeutics, Boehringer
Ingelheim, Bristol-Myers Squibb, Catabasis,
Cebix, CureDM, Diartis Pharmaceuticals, Elcelyx
Therapeutics, Eli Lilly, Exsulin, Genentech, GI Dy-
namics, GlaxoSmithKline,HalozymeTherapeutics,
F. Hoffmann-La Roche, Intarcia Therapeutics,
Johnson & Johnson, Lexicon, LipoScience, Macro-
Genics, Medtronic MiniMed, Merck, Meta-
bolic Solutions Development Co., Metabolon,
Metavention, Novan, Novo Nordisk A/S, Novella
Clinical, Orexigen Therapeutics, Osiris Therapeu-
tics, Pfizer, PhaseBio Pharmaceuticals, Quest Di-
agnostics, Rhythm Pharmaceuticals, Sanofi,
Spherix, Takeda, Tolerx, TransPharma Medical,
TransTech Pharma, Veritas, and Verva. S.D.P.
has served as a consultant or speaker for or
has received research funding fromAstraZeneca,
Boehringer Ingelheim, Bristol-Myers Squibb, Eli
Lilly, GlaxoSmithKline, Intarcia Therapeutics,
Janssen, Merck, Novartis, Novo Nordisk, Roche
Pharmaceuticals, Sanofi, and Takeda. P.D.H. has
received (or institutions with which he is associ-
ated have received) funding for his educational,
advisory, and research activities from AntriaBio,
AstraZeneca/Bristol-Myers Squibb, Boehringer
Ingelheim, Eli Lilly, GlaxoSmithKline, Hanmi,
Janssen/Johnson & Johnson, Merck, Novo Nor-
disk, Roche Diagnostics, Roche Pharmaceuticals,
Sanofi, Skyepharma, and Takeda. D.L. has served
as a consultant or received research funding
from AstraZeneca/Bristol-Myers Squibb, Janssen,
Merck, and Sanofi. M.A.N. has served on
advisory boards for, received honoraria or con-
sulting fees from, or received research funding
from Amylin, AstraZeneca, Berlin-Chemie, Boeh-
ringer Ingelheim, Bristol-Myers Squibb, Diartis
Pharmaceuticals, Eli Lilly, GlaxoSmithKline,
F. Hoffmann-La Roche, Intarcia Therapeutics,
Janssen, MannKind, Merck, MetaCure, Novartis,
Novo Nordisk, Roche Pharmaceuticals, Sanofi,
Takeda, Versartis, and Wyeth Research. I.R. has
served on the advisory boards or speakers’ bu-
reaus of or served as a consultant for Androm-
eda, AstraZeneca/Bristol-Myers Squibb, Eli Lilly,
Medscape, Merck, Novartis, Novo Nordisk, and
Sanofi. He is a stock shareholder in Insuline.
J.R. has served on advisory boards, received
honorarium or consulting fees, or received
research funding from Amylin, AstraZeneca,
Boehringer Ingelheim, Bristol-Myers Squibb,
Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Halo-
zymeTherapeutics, Intarcia Therapeutics, Janssen,
Johnson & Johnson, Lexicon, MannKind, Merck,
Novartis, Novo Nordisk, Pfizer, Roche, Sanofi,
and Takeda. M.C.R. has received honoraria for
speaking or consulting and/or research funding
through his institution from Amylin/Bristol-Myers
Squibb/AstraZeneca, Elcelyx, Eli Lilly, Sanofi, and
Valeritas. This duality of interest has been re-
viewed andmanaged by Oregon Health & Science
University. No other potential conflicts of interest
relevant to this article were reported.
References
1. Inzucchi SE, Bergenstal RM, Buse JB, et al.;
American Diabetes Association (ADA); Euro-
pean Association for the Study of Diabetes
(EASD). Management of hyperglycemia in type
2 diabetes: a patient-centered approach: posi-
tion statement of the American Diabetes Asso-
ciation (ADA) and the European Association for
the Study of Diabetes (EASD). Diabetes Care
2012;35:1364–1379
2. Garber AJ, Abrahamson MJ, Barzilay JI, et al.;
American Association of Clinical Endocrinolo-
gists. AACE comprehensive diabetes manage-
ment algorithm 2013. Endocr Pract 2013;19:
327–336
3. Home P, Riddle M, Cefalu WT, et al. Insulin
therapy in people with type 2 diabetes: oppor-
tunities and challenges? Diabetes Care 2014;37:
1499–1508
4. Zilov AV, Wenying Y, Gonzalez-Galvez G,
et al. Prevalence of complications of diabetes
in people with type 2 diabetes: data from Asia,
Europe and Latin America from the A1chieve
study. Diabetes 2011;60(Suppl. 1):A656
5. Horvath K, Jeitler K, Berghold A, et al. Long-
acting insulin analogues versusNPH insulin (human
isophane insulin) for type 2 diabetes mellitus.
Cochrane Database Syst Rev 2007;2:CD005613
6. Siebenhofer A, Plank J, Berghold A, et al.
Short acting insulin analogues versus regular
human insulin in patients with diabetes melli-
tus. Cochrane Database Syst Rev 2006;2:
CD003287
7. Holman RR, Thorne KI, Farmer AJ, et al.; 4-T
Study Group. Addition of biphasic, prandial, or
basal insulin to oral therapy in type 2 diabetes.
N Engl J Med 2007;357:1716–1730
8. Gamble JM, Simpson SH, Eurich DT,Majumdar
SR, Johnson JA. Insulin use and increased risk of
mortality in type 2 diabetes: a cohort study. Di-
abetes Obes Metab 2010;12:47–53
9. Gerstein HC, Bosch J, Dagenais GR, et al.;
ORIGIN Trial Investigators. Basal insulin and car-
diovascular and other outcomes in dysglycemia.
N Engl J Med 2012;367:319–328
10. Mellbin LG, Rydén L, Riddle MC, et al.;
ORIGIN Trial Investigators. Does hypoglycaemia
increase the risk of cardiovascular events? A re-
port from the ORIGIN trial. Eur Heart J 2013;34:
3137–3144
11. Yang YX, Hennessy S, Lewis JD. Insulin ther-
apy and colorectal cancer risk among type 2 di-
abetes mellitus patients. Gastroenterology
2004;127:1044–1050
12. Bowker SL, Majumdar SR, Veugelers P,
Johnson JA. Increased cancer-related mortality
for patients with type 2 diabetes who use sulfo-
nylureas or insulin. Diabetes Care 2006;29:254–
258
13. Currie CJ, Poole CD, Gale EA. The influence of
glucose-lowering therapies on cancer risk in type
2 diabetes. Diabetologia 2009;52:1766–1777
14. Kramer CK, Zinman B, Retnakaran R. Short-
term intensive insulin therapy in type 2 diabetes
mellitus: a systematic review andmeta-analysis.
Lancet Diabetes Endocrinol 2013;1:28–34
15. Lebovitz HE, Feinglos MN. Sulfonylurea
drugs: mechanism of antidiabetic action and
therapeutic usefulness. Diabetes Care 1978;1:
189–198
16. Reaven GM. Effect of glipizide treatment on
various aspects of glucose, insulin, and lipid me-
tabolism in patients with noninsulin-dependent
diabetes mellitus. Am J Med 1983;75:8–14
17. Lebovitz HE. Clinical utility of oral hypogly-
cemic agents in the management of patients
with noninsulin-dependent diabetes mellitus.
Am J Med 1983;75(Suppl. 5B):94–99
18. Kennedy DL, Piper JM, Baum C. Trends in
use of oral hypoglycemic agents 1964-1986. Di-
abetes Care 1988;11:558–562
19. Melander A, Lebovitz HE, Faber OK. Sulfo-
nylureas. Why, which, and how? Diabetes Care
1990;13(Suppl. 3):18–25
20. Bryan J, Crane A, Vila-Carriles WH, Babenko
AP, Aguilar-Bryan L. Insulin secretagogues, sul-
fonylurea receptors and K(ATP) channels. Curr
Pharm Des 2005;11:2699–2716
21. Desai NR, Shrank WH, Fischer MA, et al.
Patterns of medication initiation in newly diag-
nosed diabetes mellitus: quality and cost impli-
cations. Am J Med 2012;125:e1–e7
22. Zeller M, Danchin N, Simon D, et al.; French
Registry of Acute ST-Elevation and Non-ST-
Elevation Myocardial Infarction investigators.
Impact of type of preadmission sulfonylureas
on mortality and cardiovascular outcomes in di-
abetic patients with acute myocardial infarction.
J Clin Endocrinol Metab 2010;95:4993–5002
23. Goldner MG, Knatterud GL, Prout TE. Ef-
fects of hypoglycemic agents on vascular com-
plications in patients with adult-onset diabetes.
3. Clinical implications of UGDP results. JAMA
1971;218:1400–1410
24. Adler AI, Stratton IM, Neil HA, et al. Associa-
tion of systolic blood pressure with macrovascu-
lar and microvascular complications of type 2
diabetes (UKPDS 36): prospective observational
study. BMJ 2000;321:412–419
25. Riddle MC. More reasons to say goodbye to
glyburide. J Clin Endocrinol Metab 2010;95:
4867–4870
26. Lee T-M, Chou T-F. Impairment of myocar-
dial protection in type 2 diabetic patients. J Clin
Endocrinol Metab 2003;88:531–537
27. MonamiM, Luzzi C, Lamanna C, et al. Three-
year mortality in diabetic patients treated with
different combinations of insulin secretagogues
and metformin. Diabetes Metab Res Rev 2006;
22:477–482
28. Holstein A, Plaschke A, Egberts E-H. Lower
incidence of severe hypoglycaemia in patients
with type 2 diabetes treated with glimepiride
versus glibenclamide. Diabetes Metab Res Rev
2001;17:467–473
29. Hirst JA, Farmer AJ, Dyar A, Lung TWC,
Stevens RJ. Estimating the effect of sulfonylurea
on HbA1c in diabetes: a systematic review and
meta-analysis. Diabetologia 2013;56:973–984
30. Zhang Y, McCoy RG, Mason JE, Smith SA,
Shah ND, Denton BT. Second-line agents for gly-
cemic control for type 2 diabetes: are newer
agents better? Diabetes Care 2014;37:1338–
1345
31. Canaglifozin (Invokana) for type 2 diabetes.
Med Lett Drugs Ther 2013;55:37–39
32. Campbell IW. Comparing the actions of
older and newer therapies on body weight: to
2656 Safety of Medications for Type 2 Diabetes Diabetes Care Volume 37, September 2014
what extent should these effects guide the se-
lection of antidiabetic therapy? Int J Clin Pract
2010;64:791–801
33. Cleveland JC Jr, Meldrum DR, Cain BS,
Banerjee A, Harken AH. Oral sulfonylurea hypo-
glycemic agents prevent ischemic precondition-
ing in human myocardium. Two paradoxes
revisited. Circulation 1997;96:29–32
34. University Group Diabetes Program. A study
of the effects of hypoglycemia agents on vascular
complications in patients with adult-onset diabe-
tes. Diabetes 1970;19(Suppl. 2):747–830
35. American Diabetes Association. American
diabetes association policy statement: the
UGDP controversy. Diabetes Care 1979;2:1–3
36. Rytter L, Troelsen S, Beck-Nielsen H. Preva-
lence and mortality of acute myocardial infarc-
tion in patients with diabetes. Diabetes Care
1985;8:230–234
37. Aronow WS, Ahn C. Incidence of new coro-
nary events in older persons with diabetes mel-
litus and prior myocardial infarction treated
with sulfonylureas, insulin, metformin, and
diet alone. Am J Cardiol 2001;88:556–557
38. Danchin N, Charpentier G, Ledru F, et al.
Role of previous treatment with sulfonylureas
in diabetic patients with acute myocardial in-
farction: results from a nationwide French reg-
istry. Diabetes Metab Res Rev 2005;21:143–149
39. Halkin A, Roth A, Jonas M, Behar S.
Sulfonylureas are not associated with increased
mortality in diabetics treated with thrombolysis
for acute myocardial infarction. J Thromb
Thrombolysis 2001;12:177–184
40. Davis TM, Parsons RW, Broadhurst RJ,
Hobbs MS, Jamrozik K. Arrhythmias and mortal-
ity after myocardial infarction in diabetic pa-
tients. Relationship to diabetes treatment.
Diabetes Care 1998;21:637–640
41. UK Prospective Diabetes Study (UKPDS)
Group. Intensive blood-glucose control with sul-
phonylureas or insulin compared with conven-
tional treatment and risk of complications in
patients with type 2 diabetes (UKPDS 33). Lan-
cet 1998;352:837–853
42. Patel A, MacMahon S, Chalmers J, et al.;
ADVANCE Collaborative Group. Intensive blood
glucose control and vascular outcomes in pa-
tients with type 2 diabetes. N Engl J Med
2008;358:2560–2572
43. Home PD, Pocock SJ, Beck-Nielsen H, et al.;
RECORD Study Team. Rosiglitazone Evaluated
for Cardiovascular Outcomes in Oral Agent Com-
bination Therapy for Type 2 Diabetes (RECORD):
a multicentre, randomised, open-label trial.
Lancet 2009;373:2125–2135
44. Kahn SE, Haffner SM, Heise MA, et al.;
ADOPT Study Group. Glycemic durability of ro-
siglitazone, metformin, or glyburide mono-
therapy. N Engl J Med 2006;355:2427–2443
45. Monami M, Genovese S, Mannucci E. Car-
diovascular safety of sulfonylureas: a meta-
analysis of randomized clinical trials. Diabetes
Obes Metab 2013;15:938–953
46. Nagendran J, Oudit GY, Bakal JA, Light PE,
Dyck JRB, McAlister FA. Are users of sulphonyl-
ureas at the time of an acute coronary syn-
drome at risk of poorer outcomes? Diabetes
Obes Metab 2013;15:1022–1028
47. Hirsch I. First, do no harm. Clin Diabetes
2000;18:97–99
48. Hannele Y-J. Thiazolidinediones. N Engl J
Med 2004;351:1106–1118
49. Mazzone T, Meyer PM, Feinstein SB, et al.
Effect of pioglitazone compared with glimepiride
on carotid intima-media thickness in type 2 di-
abetes: a randomized trial. JAMA 2006;296:
2572–2581
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